The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 330:1639-1644 June 9, 1994 Number 23
NextNext

Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early Death
Orah S. Platt, Donald J. Brambilla, Wendell F. Rosse, Paul F. Milner, Oswaldo Castro, Martin H. Steinberg, and Panpit P. Klug

 Sign up for free e-toc
 

This Article
-Full Text

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Information on life expectancy and risk factors for early death among patients with sickle cell disease (sickle cell anemia, sickle cell-hemoglobin C disease, and the sickle cell-{beta}-thalassemias) is needed to counsel patients, target therapy, and design clinical trials.

Methods We followed 3764 patients who ranged from birth to 66 years of age at enrollment to determine the life expectancy and calculate the median age at death. In addition, we investigated the circumstances of death for all 209 adult patients who died during the study, and used proportional-hazards regression analysis to identify risk factors for early death among 964 adults with sickle cell anemia who were followed for at least two years.

Results Among children and adults with sickle cell anemia (homozygous for sickle hemoglobin), the median age at death was 42 years for males and 48 years for females. Among those with sickle cell-hemoglobin C disease, the median age at death was 60 years for males and 68 years for females. Among adults with sickle cell disease, 18 percent of the deaths occurred in patients with overt organ failure, predominantly renal. Thirty-three percent were clinically free of organ failure but died during an acute sickle crisis (78 percent had pain, the chest syndrome, or both; 22 percent had stroke). Modeling revealed that in patients with sickle cell anemia, the acute chest syndrome, renal failure, seizures, a base-line white-cell count above 15,000 cells per cubic millimeter, and a low level of fetal hemoglobin were associated with an increased risk of early death.

Conclusions Fifty percent of patients with sickle cell anemia survived beyond the fifth decade. A large proportion of those who died had no overt chronic organ failure but died during an acute episode of pain, chest syndrome, or stroke. Early mortality was highest among patients whose disease was symptomatic. A high level of fetal hemoglobin predicted improved survival and is probably a reliable childhood forecaster of adult life expectancy.


Source Information

From the Department of Medicine, Children's Hospital, the Dana-Farber Cancer Institute, and Harvard Medical School -- all in Boston (O.S.P.); New England Research Institute, Watertown, Mass. (D.J.B.); the Department of Medicine, Duke University School of Medicine, Durham, N.C. (W.F.R.); the Department of Medicine, Medical College of Georgia, Augusta (P.F.M.); the Department of Medicine, Center for Sickle Cell Disease, Howard University, Washington, D.C. (O.C.); the Hematology-Oncology Section, Jackson Veterans Affairs Medical Center, and the Department of Medicine, University of Mississippi School of Medicine -- both in Jackson (M.H.S.); and the Hematology Division, Texas Tech University Health Science Center, Amarillo (P.P.K.). The investigators who participated in this study are listed in the Appendix.

Address reprint requests to Dr. Platt at the Department of Laboratory Medicine, Children's Hospital, 300 Longwood Ave., Boston, MA 02115.

Full Text of this Article


Related Letters:

Mortality in Sickle Cell Disease
Rodgers G. P., Walker E. C., Podgor M. J., Platt O. S.
Extract | Full Text  
N Engl J Med 1994; 331:1022-1023, Oct 13, 1994. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.